1. Home
  2. PFX vs CTMX Comparison

PFX vs CTMX Comparison

Compare PFX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFX
  • CTMX
  • Stock Information
  • Founded
  • PFX 2010
  • CTMX 2008
  • Country
  • PFX United States
  • CTMX United States
  • Employees
  • PFX N/A
  • CTMX N/A
  • Industry
  • PFX Finance: Consumer Services
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFX Finance
  • CTMX Health Care
  • Exchange
  • PFX Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • PFX 99.3M
  • CTMX 89.1M
  • IPO Year
  • PFX N/A
  • CTMX 2015
  • Fundamental
  • Price
  • PFX $46.00
  • CTMX $0.91
  • Analyst Decision
  • PFX
  • CTMX Buy
  • Analyst Count
  • PFX 0
  • CTMX 6
  • Target Price
  • PFX N/A
  • CTMX $5.77
  • AVG Volume (30 Days)
  • PFX 1.1K
  • CTMX 1.1M
  • Earning Date
  • PFX 12-20-2024
  • CTMX 11-07-2024
  • Dividend Yield
  • PFX N/A
  • CTMX N/A
  • EPS Growth
  • PFX 36.92
  • CTMX N/A
  • EPS
  • PFX 9.66
  • CTMX 0.16
  • Revenue
  • PFX $22,293,269.00
  • CTMX $126,617,000.00
  • Revenue This Year
  • PFX $19.50
  • CTMX $11.79
  • Revenue Next Year
  • PFX $9.74
  • CTMX N/A
  • P/E Ratio
  • PFX $4.76
  • CTMX $5.63
  • Revenue Growth
  • PFX 14.03
  • CTMX 33.66
  • 52 Week Low
  • PFX $36.50
  • CTMX $0.91
  • 52 Week High
  • PFX $50.00
  • CTMX $5.85
  • Technical
  • Relative Strength Index (RSI)
  • PFX 33.76
  • CTMX 32.42
  • Support Level
  • PFX $44.56
  • CTMX $0.98
  • Resistance Level
  • PFX $47.11
  • CTMX $1.08
  • Average True Range (ATR)
  • PFX 0.61
  • CTMX 0.06
  • MACD
  • PFX -0.20
  • CTMX -0.00
  • Stochastic Oscillator
  • PFX 26.47
  • CTMX 0.00

About PFX PhenixFIN Corporation

PhenixFIN Corp formerly Medley Capital Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: